Drug resistance of EGFR-TKI for non-small cell lung cancer
10.3969/j.issn.1000-8179.20130889
- VernacularTitle:EGFR-TKI治疗非小细胞肺癌的耐药机制进展研究
- Author:
Jun LIU
;
Changli WANG
- Publication Type:Journal Article
- Keywords:
non-small cell lung cancer;
epidermal growth factor receptor;
tyrosine kinase inhibitor (EGFR-TKI)
- From:
Chinese Journal of Clinical Oncology
2013;(19):1207-1209
- CountryChina
- Language:Chinese
-
Abstract:
The incidence of lung cancer ranks the first among malignancies in China. Studies on molecular-targeted therapy with epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) have atracted more attention. However, many patients with non-small cell lung cancer (NSCLC) manifest primary symptoms at the beginning of therapy;other patients develop drug resistance after they receive EGFR-TKI treatment for a period. This review describes the progress on drug resistance mechanisms of EGFR-TKIs at a molecular level and the significance of such inhibitors in clinical application.
